FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897979818> ?p ?o ?g. }

• W2897979818 endingPage "1548" @default.
• W2897979818 startingPage "1548" @default.
• W2897979818 abstract "ImportanceChronic obstructive pulmonary disease (COPD) is a major global health issue and theophylline is used extensively. Preclinical investigations have demonstrated that low plasma concentrations (1-5 mg/L) of theophylline enhance antiinflammatory effects of corticosteroids in COPD.ObjectiveTo investigate the effectiveness of adding low-dose theophylline to inhaled corticosteroids in COPD.Design, Setting, and ParticipantsThe TWICS (theophylline with inhaled corticosteroids) trial was a pragmatic, double-blind, placebo-controlled, randomized clinical trial that enrolled patients with COPD between February 6, 2014, and August 31, 2016. Final follow-up ended on August 31, 2017. Participants had a ratio of forced expiratory volume in the first second to forced vital capacity (FEV1/FVC) of less than 0.7 with at least 2 exacerbations (treated with antibiotics, oral corticosteroids, or both) in the previous year and were using an inhaled corticosteroid. This study included 1578 participants in 121 UK primary and secondary care sites.InterventionsParticipants were randomized to receive low-dose theophylline (200 mg once or twice per day) to provide plasma concentrations of 1 to 5 mg/L (determined by ideal body weight and smoking status) (n = 791) or placebo (n = 787).Main Outcomes and MeasuresThe number of participant-reported moderate or severe exacerbations treated with antibiotics, oral corticosteroids, or both over the 1-year treatment period.ResultsOf the 1567 participants analyzed, mean (SD) age was 68.4 (8.4) years and 54% (843) were men. Data for evaluation of the primary outcome were available for 1536 participants (98%) (772 in the theophylline group; 764 in the placebo group). In total, there were 3430 exacerbations: 1727 in the theophylline group (mean, 2.24 [95% CI, 2.10-2.38] exacerbations per year) vs 1703 in the placebo group (mean, 2.23 [95% CI, 2.09-2.37] exacerbations per year); unadjusted mean difference, 0.01 (95% CI, -0.19 to 0.21) and adjusted incidence rate ratio, 0.99 (95% CI, 0.91-1.08). Serious adverse events in the theophylline and placebo groups included cardiac, 2.4% vs 3.4%; gastrointestinal, 2.7% vs 1.3%; and adverse reactions such as nausea (10.9% vs 7.9%) and headaches (9.0% vs 7.9%).Conclusions and RelevanceAmong adults with COPD at high risk of exacerbation treated with inhaled corticosteroids, the addition of low-dose theophylline, compared with placebo, did not reduce the number COPD exacerbations over a 1-year period. The findings do not support the use of low-dose theophylline as adjunctive therapy to inhaled corticosteroids for the prevention of COPD exacerbations.Trial Registrationisrctn.org Identifier: ISRCTN27066620." @default.
• W2897979818 created "2018-10-26" @default.
• W2897979818 creator A5001203491 @default.
• W2897979818 creator A5009008744 @default.
• W2897979818 creator A5017361282 @default.
• W2897979818 creator A5019479654 @default.
• W2897979818 creator A5024774615 @default.
• W2897979818 creator A5030258071 @default.
• W2897979818 creator A5034189480 @default.
• W2897979818 creator A5038268634 @default.
• W2897979818 creator A5038285954 @default.
• W2897979818 creator A5038358028 @default.
• W2897979818 creator A5044898274 @default.
• W2897979818 creator A5047979811 @default.
• W2897979818 creator A5048090792 @default.
• W2897979818 creator A5052175038 @default.
• W2897979818 creator A5056602092 @default.
• W2897979818 creator A5061749118 @default.
• W2897979818 creator A5061925824 @default.
• W2897979818 creator A5070372650 @default.
• W2897979818 creator A5076371917 @default.
• W2897979818 creator A5079355438 @default.
• W2897979818 creator A5080457552 @default.
• W2897979818 date "2018-10-16" @default.
• W2897979818 modified "2023-10-17" @default.
• W2897979818 title "Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD" @default.
• W2897979818 cites W1979518810 @default.
• W2897979818 cites W2002726093 @default.
• W2897979818 cites W2013407710 @default.
• W2897979818 cites W2041056515 @default.
• W2897979818 cites W2054931962 @default.
• W2897979818 cites W2064201717 @default.
• W2897979818 cites W2078552229 @default.
• W2897979818 cites W2099368483 @default.
• W2897979818 cites W2110040793 @default.
• W2897979818 cites W2110472610 @default.
• W2897979818 cites W2112162293 @default.
• W2897979818 cites W2124518659 @default.
• W2897979818 cites W2125078269 @default.
• W2897979818 cites W2127938597 @default.
• W2897979818 cites W2129238234 @default.
• W2897979818 cites W2138277216 @default.
• W2897979818 cites W2141402647 @default.
• W2897979818 cites W2149849734 @default.
• W2897979818 cites W2150171005 @default.
• W2897979818 cites W2164147349 @default.
• W2897979818 cites W2166432084 @default.
• W2897979818 cites W2341771388 @default.
• W2897979818 cites W2473786944 @default.
• W2897979818 cites W2512624858 @default.
• W2897979818 cites W2785999277 @default.
• W2897979818 cites W2805013685 @default.
• W2897979818 cites W4247192806 @default.
• W2897979818 cites W4250109354 @default.
• W2897979818 cites W4251855335 @default.
• W2897979818 cites W4252956197 @default.
• W2897979818 cites W4254423821 @default.
• W2897979818 doi "https://doi.org/10.1001/jama.2018.14432" @default.
• W2897979818 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6233797" @default.
• W2897979818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30326124" @default.
• W2897979818 hasPublicationYear "2018" @default.
• W2897979818 type Work @default.
• W2897979818 sameAs 2897979818 @default.
• W2897979818 citedByCount "61" @default.
• W2897979818 countsByYear W28979798182019 @default.
• W2897979818 countsByYear W28979798182020 @default.
• W2897979818 countsByYear W28979798182021 @default.
• W2897979818 countsByYear W28979798182022 @default.
• W2897979818 countsByYear W28979798182023 @default.
• W2897979818 crossrefType "journal-article" @default.
• W2897979818 hasAuthorship W2897979818A5001203491 @default.
• W2897979818 hasAuthorship W2897979818A5009008744 @default.
• W2897979818 hasAuthorship W2897979818A5017361282 @default.
• W2897979818 hasAuthorship W2897979818A5019479654 @default.
• W2897979818 hasAuthorship W2897979818A5024774615 @default.
• W2897979818 hasAuthorship W2897979818A5030258071 @default.
• W2897979818 hasAuthorship W2897979818A5034189480 @default.
• W2897979818 hasAuthorship W2897979818A5038268634 @default.
• W2897979818 hasAuthorship W2897979818A5038285954 @default.
• W2897979818 hasAuthorship W2897979818A5038358028 @default.
• W2897979818 hasAuthorship W2897979818A5044898274 @default.
• W2897979818 hasAuthorship W2897979818A5047979811 @default.
• W2897979818 hasAuthorship W2897979818A5048090792 @default.
• W2897979818 hasAuthorship W2897979818A5052175038 @default.
• W2897979818 hasAuthorship W2897979818A5056602092 @default.
• W2897979818 hasAuthorship W2897979818A5061749118 @default.
• W2897979818 hasAuthorship W2897979818A5061925824 @default.
• W2897979818 hasAuthorship W2897979818A5070372650 @default.
• W2897979818 hasAuthorship W2897979818A5076371917 @default.
• W2897979818 hasAuthorship W2897979818A5079355438 @default.
• W2897979818 hasAuthorship W2897979818A5080457552 @default.
• W2897979818 hasBestOaLocation W28979798181 @default.
• W2897979818 hasConcept C126322002 @default.
• W2897979818 hasConcept C138885662 @default.
• W2897979818 hasConcept C177713679 @default.
• W2897979818 hasConcept C2776042228 @default.
• W2897979818 hasConcept C2776780178 @default.
• W2897979818 hasConcept C2776804153 @default.

• next